ClinicalTrials.gg
RecruitingNCT07427472DESTINY-FHUpdated Jun 24, 2026

"Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)"

An interventional study of Coronary computed tomography angiography in Heterozygous Familial Hypercholesterolemia (HeFH), sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 3 sites in France. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
30 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Coronary Artery Disease by Assistance Publique - Hôpitaux de Paris — 3 open to participants now, 3 under way, none of them phase 3. Coronary Artery Disease · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
8th of 17
300 · median 260
Started
2026
the only one that year
No phase
9 of 20
3 open now
Registered
20th of 20
by date

Among the 20 studies in Coronary Artery Disease by Assistance Publique - Hôpitaux de Paris, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2026, is one of 9 with no phase, and was the 20th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

3 of the 20 studies in Coronary Artery Disease by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 30 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Coronary Artery Disease by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

This multicenter, non-randomized interventional study aims to assess coronary artery disease progression over 5 years in patients with genetically confirmed heterozygous familial hypercholesterolemia (HeFH), using coronary computed tomography angiography (CCTA).

The primary endpoint is the visual evaluation of coronary stenosis using CAD-RADS v2.0, identifying changes between baseline (2018-2022) and study inclusion. The study will enroll 300 patients (100 protected, 200 non-protected) from La Pitié-Salpêtrière hospital and Saint Antoine Hospital (Paris). Participation lasts up to one week. Total study duration is 2 years, with extended follow-up through routine care data over 10 years.

Read the detailed description

HeFH is an autosomal dominant genetic disorder characterized by lifelong elevated LDL-C levels, which significantly increase the risk of premature coronary atherosclerosis. Cardiovascular risk stratification in HeFH remains challenging due to limitations of traditional risk scores and stress testing. The coronary artery calcium (CAC) score is a useful tool for reclassifying cardiovascular risk but fails to detect non-calcified plaques, which may be prevalent in HeFH despite a CAC score of zero. Previous studies suggest a prevalence of non-calcified plaques as high as 30% in molecularly diagnosed HeFH patients.

This multicenter interventional, non-randomized comparative study aims to evaluate the progression of coronary artery disease over a 5-year period in patients with genetically confirmed heterozygous familial hypercholesterolemia (HeFH). Using coronary computed tomography angiography (CCTA), the study will assess both calcified and non-calcified plaque burden in this high-risk population.

The primary outcome is the visual, semi-quantitative evaluation of coronary stenosis severity using CAD-RADS v2.0 classification to identify high-risk plaques and categorize patients as having regression, stability, or progression of coronary disease based on changes in CAD-RADS categories between baseline (2018-2022) and the DESTINY-FH study visit.

The study will enroll 300 patients (100 "protected" and 200 "non-protected") from La Pitié-Salpêtrière hospital and Saint Antoine Hospital (Paris). Individual participation will last from one day to one week. Total study duration is 2 years, with additional 10-year follow-up using routinely collected medical records.

03

Conditions studied

  • Heterozygous Familial Hypercholesterolemia (HeFH)

Keywords

  • Coronary Artery Disease
  • Atherosclerosis
  • Coronary Plaque Vulnerability
  • Cardiovascular Risk
  • Cardiovascular Events
04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with heterozygous familial hypercholesterolemia
  2. Aged 30 to 60 years.
  3. Patients who underwent a CAC score and a coronary CT angiogram at least 5 years ago, exclusively at the same imaging center (ICT de la Pitié Salpetrière).
  4. Patient asymptomatic for exertional chest pain at the time of CCTA
  5. Clinical examination performed
  6. Beneficiary of a social protection scheme or entitled person (excluding AME)
  7. Patient informed and consent form signed

Exclusion criteria

Exclusion Criteria:

  1. Patient under guardianship, or unable to give consent
  2. Pregnancy, breast-feeding
  3. Technical : weight > 250 kg
  4. Simultaneous participation in other interventional research involving the human body, or period of exclusion following previous research involving the human body still in progress.
  5. Adults subject to a legal protection order
  6. Contraindication to esmolol and/or atenolol
  7. Only for patients who need to undergo a CT angiogram and a thoraco-abdominal-pelvic CT scan:

    • Renal insufficiency (LC\<60)
    • Unbalanced diabetes when acquiring a previous coronary angioscanner
    • Personal history of cardiovascular disease and myocardial infarction at the time of CCTA
    • Contraindication to iodinated contrast media
    • Patient having already had an adverse event (AE) during the acquisition of a prior coronary angioscanner
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Other
    Patients with protected and unprotected familial hypercholesterolemia

    Coronary computed tomography angiography with injection of iodinated contrast material

    Other: Coronary computed tomography angiography

Interventions

  • OtherCoronary computed tomography angiography

    Coronary computed tomography angiography with injection of iodinated contrast material

06

What researchers measure

Primary outcomes

  1. Progression of coronary artery disease over 5 years in patients with heterozygous familial hypercholesterolemia

    The evolution of coronary artery disease will be assessed over 5 years in patients with heterozygous familial hypercholesterolemia using coronary CT angiography (CTA). The number of patients with regression, stability, or progression of coronary stenosis will be determined using semi-quantitative visual assessment of coronary stenoses according to the CAD-RADS v2.0 classification, including visual characterization of high-risk plaque features.Time Frame: 5 years Unit of Measure: Number and percentage of participants with regression, stability, or progression of coronary stenosis

    Time frame: 1 day

Secondary outcomes

  1. Change in total coronary plaque volume, lesion type, and proximal aortic calcifications.

    Assessment of coronary artery disease progression in HeFH patients using 5-years follow-up CCTA. CAD-RADS v2.0 will be used to evaluate changes in stenosis severity and identify high-risk plaques. Progression will be defined by a change in CAD-RADS category between first CCTA (defined as baseline, realized between 2018 and 2022) and inclusion in DESTINY-FH

    Time frame: 1 day

  2. Survival curve of major cardiovascular events incidence.

    Incidence of myocardial infarction, ischemic stroke, transient ischemic attack, and coronary, carotid, and/or femoral revascularization since baseline CCTA in both groups

    Time frame: 1 day

  3. Cox regression analysis of cardiovascular event occurrence and associated clinical, biological, and omics data.

    Evaluation of the association between cardiovascular event occurrence (as defined in outcome 2) and clinical, biological, omics, and macro/microvascular data using Cox regression analysis.

    Time frame: 1 day

  4. Linear regression of clinical and biological variables by CAD-RADS category change.

    Comparison and linear regression of clinical and biological explanatory variables according to change in CAD-RADS category between baseline and inclusion, in the overall cohort and stratified by groups.

    Time frame: 1 day

  5. Comparison of omics data by plaque volume change and CAD-RADS category shift.

    Comparison of omics data based on the quantitative change in total coronary plaque volume or change in CAD-RADS category between baseline and inclusion, stratified by group.

    Time frame: 1 day

  6. Baseline prevalence of carotid plaque by group

    Presence or absence of carotid plaque will be assessed at baseline using coronary CT angiography (CTA). Prevalence of carotid plaque will be compared between groups at baseline. Unit of Measure: % of participants with carotid plaque

    Time frame: 1 day

  7. Baseline prevalence of femoral plaque by group

    Presence or absence of femoral plaque will be assessed at baseline using duplex Doppler ultrasound. Prevalence of femoral plaque will be compared between groups at baseline. Unit of Measure:% of participants with femoral plaque

    Time frame: 1 day

  8. Baseline aortic valve calcium score by group

    Aortic valve calcium score will be measured at baseline using non-contrast cardiac CT according to the Agatston method. Scores will be compared between groups at baseline. Unit of Measure:Agatston score (Agatston units)

    Time frame: 1 day

  9. Baseline thoracic aorta calcium score by group

    Thoracic aorta calcium score will be measured at baseline using non-contrast cardiac CT according to the Agatston method. Scores will be compared between groups at baseline. Unit of Measure:Agatston score (Agatston units)

    Time frame: 1 day

  10. Baseline diameters of the ascending and descending aorta by group

    Aortic diameters will be measured at baseline using CT angiography (mm). Measurements will be compared between groups at baseline. Unit of Measure: Aortic diameter (mm).

    Time frame: 1 day

  11. Correlation between baseline carotid plaque presence and change in coronary plaque volume

    Presence or absence of carotid plaque will be assessed at baseline using duplex Doppler ultrasound. Its correlation with change in total coronary plaque volume between baseline and follow-up will be evaluated. Coronary plaque volume will be quantified using coronary CT angiography (CTA). Unit of Measure:Change in coronary plaque volume (mm³)

    Time frame: Baseline to 5 years

  12. Correlation between baseline femoral plaque presence and change in coronary plaque volume

    Presence or absence of femoral plaque will be assessed at baseline using duplex Doppler ultrasound. Its correlation with change in total coronary plaque volume between baseline and follow-up will be evaluated. Coronary plaque volume will be quantified using coronary CT angiography (CTA). Unit of Measure: Change in coronary plaque volume (mm³)

    Time frame: Baseline to 5 years

  13. Correlation between baseline CAC score (aortic valve and thoracic aorta) and coronary plaque progression

    Coronary artery calcium (CAC) score will be measured at baseline using non-contrast CT (Agatston method). The CAC score of the aortic valve and thoracic aorta will be correlated with change in total coronary plaque volume (mm³) and CAD-RADS category between baseline and follow-up, as assessed by CTA. Unit of Measure: CAC score (Agatston units); change in coronary plaque volume (mm³); change in CAD-RADS category.

    Time frame: 1 day

  14. Correlation between baseline aortic diameters and coronary plaque progression

    Aortic diameters (ascending and thoracic aorta) will be measured at baseline using CT angiography (mm). Aortic diameter values will be correlated with change in total coronary plaque volume (mm³) and plaque vulnerability features on coronary CTA between baseline and follow-up. Unit of Measure: Aortic diameter (mm); change in coronary plaque volume (mm³).

    Time frame: 1 day

  15. Baseline epicardial fat volume by group

    Epicardial fat volume will be measured at baseline using coronary CT angiography (CTA). Volumes will be compared between groups at baseline. Unit of Measure: Epicardial fat volume (cm³)

    Time frame: 1 day

  16. Baseline epicardial fat density by group

    Epicardial fat density will be measured at baseline using coronary CT angiography (CTA). Density will be compared between groups at baseline. Unit of Measure: Epicardial fat density (Hounsfield Units, HU)

    Time frame: 1 day

  17. Baseline subdiaphragmatic abdominal adipose tissue volume at L1 by group

    Subdiaphragmatic abdominal adipose tissue volume will be quantified at the level of the first lumbar vertebra (L1) using non-contrast CT. Segmentation will be performed using standard attenuation thresholds for adipose tissue. Relative adipose tissue volume will be compared between groups at baseline. Unit of Measure:Relative adipose tissue volume (%)

    Time frame: 1 day

  18. Baseline subdiaphragmatic abdominal adipose tissue density at L1 by group

    Mean attenuation of subdiaphragmatic abdominal adipose tissue will be measured at the level of L1 using non-contrast CT. Mean density will be compared between groups at baseline. Unit of Measure:Mean adipose tissue density (Hounsfield Units, HU)

    Time frame: 1 day

  19. Baseline arterial wall thickness by group

    Arterial wall thickness will be measured at baseline using adaptive optics retinal imaging. Values will be compared between groups at baseline. Unit of Measure: Wall thickness (µm).

    Time frame: 1 day

  20. Baseline arterial lumen diameter by group

    Arterial lumen diameter will be measured at baseline using adaptive optics retinal imaging. Values will be compared between groups at baseline. Unit of Measure: Lumen diameter (µm).

    Time frame: 1 day

  21. Baseline arterial wall-to-lumen ratio by group

    Wall-to-lumen ratio will be calculated at baseline using adaptive optics retinal imaging. Ratios will be compared between groups at baseline. Unit of Measure: Wall-to-lumen ratio (unitless).

    Time frame: 1 day

  22. Baseline arterial wall cross-sectional area by group

    Arterial wall cross-sectional area will be measured at baseline using adaptive optics retinal imaging. Values will be compared between groups at baseline. Unit of Measure: wall cross-sectional area (µm²).

    Time frame: 1 day

  23. Correlation between retinal arterial wall thickness and coronary plaque progression

    Arterial wall thickness will be measured at baseline using adaptive optics retinal imaging. Its correlation with change in total coronary plaque volume (mm³) and CAD-RADS category between baseline and follow-up will be evaluated.Unit of Measure: Wall thickness (µm); change in coronary plaque volume (mm³); CAD-RADS category

    Time frame: 1 day

  24. Correlation between retinal lumen diameter and coronary plaque progression

    Arterial lumen diameter will be measured at baseline using adaptive optics retinal imaging. Its correlation with change in total coronary plaque volume (mm³) and CAD-RADS category between baseline and follow-up will be evaluated. Unit of Measure: Lumen diameter (µm); change in coronary plaque volume (mm³); CAD-RADS category.

    Time frame: 1 day

  25. Correlation between retinal wall-to-lumen ratio and coronary plaque progression

    Wall-to-lumen ratio will be measured at baseline using adaptive optics retinal imaging. Its correlation with change in total coronary plaque volume (mm³) and CAD-RADS category between baseline and follow-up will be evaluated. Unit of Measure: Wall-to-lumen ratio (unitless); change in coronary plaque volume (mm³); CAD-RADS category

    Time frame: 1 day

  26. Correlation between retinal arterial wall cross-sectional area and coronary plaque progression

    Arterial wall cross-sectional area will be measured at baseline using adaptive optics retinal imaging. Its correlation with change in total coronary plaque volume (mm³) and CAD-RADS category between baseline and follow-up will be evaluated. Unit of Measure: Cross-sectional area (mm²); change in coronary plaque volume (mm³); CAD-RADS category

    Time frame: 1 day

  27. Comparison of liver and spleen density at baseline between groups

    Comparison of unenhanced liver and spleen density between groups at baseline.

    Time frame: 1 day

  28. Gut microbiota composition at baseline using metabolomics and metagenomics.

    Characterization of gut microbiota at baseline in both groups using targeted and untargeted metabolomics (e.g., secondary bile acids, choline/tryptophan/cholesterol derivatives, short-chain fatty acids) and metagenomic sequencing with bioinformatic analysis of bacterial populations.

    Time frame: 1 day

  29. Association between baseline omics data and coronary plaque progression.

    Comparison of baseline omics data according to the change in total coronary plaque volume or CAD-RADS category between baseline and inclusion, stratified by group.

    Time frame: 1 day

  30. Change in gut microbiota composition between baseline and inclusion

    Comparison of gut microbiota composition between baseline (for patients previously included in the FHCALC study) and inclusion, in both groups

    Time frame: 1 day

  31. Comparison of arterial stiffness at baseline between groups.

    Comparison of arterial stiffness measurements between groups at baseline.

    Time frame: 1 day

  32. SF-36 Health Survey score at inclusion

    The SF-36 Health Survey will be administered at inclusion. The total score and domain scores will be recorded, ranging from 0 to 100, where higher scores indicate better health status. Unit of Measure: Score (0-100)

    Time frame: 1 day

  33. Seattle Angina Questionnaire-7 (SAQ-7) score at inclusion

    The SAQ-7 will be administered at inclusion. Scores range from 0 to 100, with higher scores indicating less angina and better functional status. Unit of Measure: Score (0-100)

    Time frame: 1 day

  34. Rose Dyspnea Scale score at inclusion

    The Rose Dyspnea Scale will be administered at inclusion. Scores range from 0 to 4, where higher scores indicate greater breathlessness. Unit of Measure: Score (0-4)

    Time frame: 1 day

  35. Patient Health Questionnaire-2 (PHQ-2) score at inclusion

    The PHQ-2 will be administered at inclusion. Scores range from 0 to 6, with higher scores indicating greater depressive symptoms. Unit of Measure: Score (0-6)

    Time frame: 1 day

  36. Hospital Anxiety and Depression Scale (HADS) score at inclusion

    The HADS will be administered at inclusion. Scores range from 0 to 21 for anxiety and 0 to 21 for depression, with higher scores indicating greater symptom severity. Unit of Measure: Score (0-21) for anxiety; Score (0-21) for depression

    Time frame: 1 day

  37. CONSTANCES study questionnaire scores at inclusion

    Selected standardized questionnaires from the CONSTANCES cohort study will be administered at inclusion. Scores will be recorded according to the original scoring system of each questionnaire (specific scales and units to be defined). Unit of Measure: As per original scoring system of each CONSTANCES questionnaire

    Time frame: 1 day

  38. Incidence of major cardiovascular events at 5 and 10 years

    Occurrence of major cardiovascular events-including myocardial infarction, ischemic stroke, transient ischemic attack (TIA), and coronary, carotid, and/or femoral revascularization-will be recorded. Events will be ascertained through clinical records and patient interviews. Survival curves will be generated to estimate cumulative incidence at both 5- and 10-year follow-up.

    Time frame: 5 and 10 years

07

Study locations

1 of 3 sites recruiting
  • Plateau d'investigation clinique (PIC) IHU-ICAN
    Paris, 75013, France
    Not yet recruiting
  • APHP- Hospital Saint-Antoine
    Paris, Île-de-France Region 75013, France
    Not yet recruiting
    • Franck BOCCARA, MD, PhD · Contactfranck.boccara@aphp.fr · 33(0)1 49 28 24 49
    • Franck BOCCARA, MD, PhD · Principal investigator
  • APHP-Sorbonne, Pitié Salpêtrière Hospital
    Paris, Île-de-France Region 75013, France
    Recruiting
    • Antonio GALLO, MD, PhD · Contactantonio.gallo@aphp.fr · 33(0)1 42 17 57 74
    • Antonio GALLO, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Data are available upon reasonable request The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodologically sound proposal

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 24 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Feb 23, 2026
StartActual
Jun 19, 2026
Primary completionEst.
Jun 19, 2028
CompletionEst.
Jun 19, 2036
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07427472
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Jun 19, 2026
Primary completion
Jun 19, 2028 (estimated)
Completion
Jun 19, 2036 (estimated)
Last update
Jun 24, 2026

Study contacts

Antonio GALLO, MD, PhD
Contact
antonio.gallo@aphp.fr
33(0)1 42 17 57 74
Franck BOCCARA, MD, PhD
Contact
franck.boccara@aphp.fr
33(0)1 49 28 24 49

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion